Celcuity Secures $500 Million Credit Facility Following Positive Phase 3 Data for Gedatolisib in Advanced Breast Cancer
核心洞察
Celcuity has upsized its senior secured credit facility to $500 million with Innovatus Capital Partners (搜索) and Oxford Finance (搜索), including $350 million in committed capital and up to $150 million at mutual discretion.
The financing follows positive topline data from the PIK3CA wild-type cohort of the pivotal VIKTORIA-1 Phase 3 clinical study evaluating gedatolisib in advanced breast cancer (搜索) patients.
The enhanced financial structure provides funding for the rolling NDA submission to FDA via the RTOR program and commercial launch preparations for gedatolisib.
Celcuity Inc., a clinical-stage biotechnology company developing targeted oncology therapies, has significantly strengthened its financial position by upsizing its senior secured credit facility to $500 million. The amended agreement with Innovatus Capital Partners (搜索) and Oxford Finance (搜索) provides $350 million in committed capital and up to $150 million at the mutual discretion of Celcuity and its lenders.
The financing comes on the heels of positive topline data from the PIK3CA wild-type cohort of Celcuity's pivotal VIKTORIA-1 Phase 3 clinical study, which is evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer (搜索).
Enhanced Capital Structure and Milestone Funding
The amended credit facility adds $170 million in new committed capital, with structured milestone-based funding tied to regulatory and commercial achievements. Specifically, $100 million becomes available upon FDA approval of gedatolisib in second-line wild-type advanced breast cancer (搜索) patients post-CDK4/6 (搜索) inhibitor therapy, while an additional $120 million is contingent upon achieving certain commercial revenue milestones.
At the closing of the amendment, Celcuity received initial funding of $30 million, bringing the total outstanding term loan to $130 million. The improved structure extends the interest-only period by 14 months, with an additional seven-month extension available upon FDA approval, while also extending the facility's maturity date by six months.
Gedatolisib Development Program
Gedatolisib represents a differentiated approach to targeting the PI3K (搜索)/AKT/mTOR pathway as a potent, pan-PI3K and mTORC1/2 (搜索) inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties distinguish it from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or in combination.
The VIKTORIA-1 Phase 3 trial has completed enrollment and reported topline data for the PIK3CA wild-type cohort, while continuing to enroll patients for the PIK3CA mutant cohort. Beyond breast cancer, Celcuity is advancing gedatolisib in multiple indications, including an ongoing Phase 1/2 trial (CELC-G-201) evaluating the drug in combination with darolutamide in patients with metastatic castration resistant prostate cancer (搜索).
Strategic Funding Utilization
The enhanced financial flexibility positions Celcuity to support its rolling submission to FDA of its New Drug Application via FDA's Real-Time Oncology Review (RTOR) program. The funding will also support commercial launch preparations for gedatolisib and other strategic initiatives as the company advances its lead therapeutic candidate toward potential market approval.
Additionally, Celcuity is conducting VIKTORIA-2, a Phase 3 clinical trial evaluating gedatolisib plus a CDK4/6 (搜索) inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer (搜索), which is currently enrolling patients.